← Back to Search
Mutational Analysis Of The β-tubulin Gene In Lung Cancer
J. Tsurutani, T. Komiya, H. Uejima, H. Tada, Negoro Syunichi, M. Oka, S. Kohno, M. Fukuoka, K. Nakagawa
Published 2002 · Biology
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Recently, several studies have suggested that a major mechanism of resistance to paclitaxel might involve mutations in the β-tubulin gene in tumor cells. To investigate the frequency of β-tubulin mutations in Japanese patients with small and non-small cell lung cancer, direct sequence analysis following reverse transcription-polymerase chain reaction (RT-PCR) of the β-tubulin gene was performed using total RNA from 20 lung cancer cell lines and 22 specimens from lung cancer patients. First-strand cDNA sequence analysis of the 42 samples showed silent mutations at codon 180 of the β-tubulin gene, which encodes the GTP-binding site of the protein, and codons 195 and 217. However, neither missense nor non-sense mutations affecting microtubule dynamics, within or near the GTP-binding site of the β-tubulin gene, were detected. These results indicate that β-tubulin gene mutations might not play a major role in the mechanism of resistance to paclitaxel in Japanese lung cancer patients. Further investigations are needed to clarify the mechanism of drug resistance.
This paper references
CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin
F. Cabral (1980)
Diverse mechanisms in the generation of human beta-tubulin pseudogenes.
C. Wilde (1982)
Evidence that a human β-tubulin pseudogene is derived from its corresponding mRNA
C. Wilde (1982)
Evolutionary history of a multigene family: An expressed human β-tubulin gene and three processed pseudogenes
M. G. Lee (1983)
Identification of two human beta-tubulin isotypes.
J. Hall (1983)
Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.
N. Kartner (1983)
Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
W. Harker (1985)
Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin
M. J. Schibler (1986)
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.
K. Ueda (1987)
The direct activation of human multidrug resistance gene (MDR1) by anticancer agents.
K. Kohno (1989)
Resistance to antineoplastic drugs
D. Kessel (1989)
P‐glycoprotein and resistance to anticancer drugs
V. Ling (1992)
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W. Mcguire (1996)
Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.
D. Johnson (1996)
Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.
W. Mcguire (1996)
Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization*
P. Giannakakou (1997)
K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
Y. Fukuyama (1997)
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
B. Brockstein (1998)
Preferential Binding of E7010 to Murine β3‐Tubulin and Decreased β3‐Tubulin in E7010‐resistant Cell Lines
Y. Iwamoto (1998)
Overexpression of class I, II or IVb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel.
K. Blade (1999)
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.
M. Monzó (1999)
A β-Tubulin Leucine Cluster Involved in Microtubule Assembly and Paclitaxel Resistance* 210
M. Gonzalez-Garay (1999)
Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol
M. Kavallaris (1999)
This paper is referenced by
PRP4K IS A NOVEL HER2-REGULATED MODIFIER OF ANOIKIS AND TAXANE RESISTANCE
Dale P. Corkery (2018)
Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
R. Matesanz (2014)
Advances in personalized therapy for lung cancer.
Eric S Kim (2013)
Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways
Z. Li (2013)
New insights into mechanisms of resistance to microtubule inhibitors.
Anutosh Ganguly (2011)
Src family kinases and paclitaxel sensitivity
X. Le (2011)
Lung Cancer Resistance to Chemotherapy
D. J. Stewart (2010)
Human Mutations That Confer Paclitaxel Resistance
Shanghua Yin (2010)
Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
C. Stengel (2010)
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.
David J Stewart (2010)
A mutation in β‐tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel‐resistant prostate cancer cell line
T. Hara (2010)
Ixabepilone: targeting βIII-tubulin expression in taxane-resistant malignancies
C. Dumontet (2009)
Serum Osteopontin Levels are Highly Prognostic for Survival in Advanced Non-small Cell Lung Cancer: Results from JMTO LC 0004
S. Isa (2009)
Microtubule Stabilizing Agents
S. Horwitz (2008)
Mechanisms of Resistance to Drugs That Interfere with Microtubule Assembly
F. Cabral (2008)
Molecular mechanisms of patupilone resistance.
S. Mozzetti (2008)
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
A. Chien (2008)
Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region.
G. Raspaglio (2008)
Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes
E. Galletti (2007)
Strategies for the development of novel Taxol-like agents.
S. Mooberry (2007)
Expression of beta-tubulin isotypes in human primary ovarian carcinoma.
Y. Ohishi (2007)
The Roles of β-Tubulin Mutations and Isotype Expression in Acquired Drug Resistance
J. T. Huzil (2007)
Pharmacogenetic Studies of Paclitaxel in Ovarian Cancer : focus on interindividual differences in pharmacodynamics and pharmacokinetics
H. Gréen (2007)
Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins
S. Tommasi (2007)
Preclinical Pharmacologic Evaluation of MST-997, an Orally Active Taxane with Superior In vitro and In vivo Efficacy in Paclitaxel- and Docetaxel-Resistant Tumor Models
D. Sampath (2006)
Resistance To Taxanes
L. Greenberger (2006)
β-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues
H. Gréen (2006)
Predictive factors for response to docetaxel in human breast cancers
S. Noguchi (2006)
Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines
J. Chang (2006)
Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.
T. Saijo (2006)
Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
S. Mozzetti (2005)
Mechanisms Involved in Chemoresistance in Ovarian Cancer
Kar-San Ling (2005)See more